Treatment for spinocerebellar ataxia type 31 (SCA31)

摘要

PROBLEM TO BE SOLVED: To provide a novel therapy based on the onset mechanism of spinocerebellar ataxia type 31 (SCA31).SOLUTION: The invention provides a therapeutic agent for spinocerebellar ataxia type 31 (SCA31) comprising RNA binding proteins selected from TDP-43 or FUS/TLS, or a fragment comprising these RNA binding regions.SELECTED DRAWING: None